Director buying at GeneNews (GEN)

Director buying at GeneNews (V:GEN)

Rory Riggs, a Director, acquired 7,022,126 Common Shares on a direct ownership basis at a price of $0.080 through a private transaction on May 22nd, 2018. The insider also acquired 3,511,063 Warrants with an exercise price of $0.120 for 3 years. This represents a $561,770 investment into the company's shares and an account share holdings change of greater than 100%.

GeneNews is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

GeneNews Ltd is a Canada-based company focused on developing and commercializing proprietary molecular diagnostic tests for early detection of cancer. It has developed Sentinel Principle platform technology, which determines biomarkers from whole blood. In additional, the Company offers ColonSentry product, it is a blood test to determine an individual's current risk for having colorectal cancer. The Company operates within the biotechnology, molecular diagnostic and genomic biomarker industry. GeneNews has subsidiaries in Canada and the United states. The Company's partners include JTS Health Partners and NueHealth, which are located in the United States.